Recognition of Tevogen Bio: Tevogen Bio Holdings Inc. has been named in BINJE's BEST Health Care 2025 list, highlighting its commitment to health equity and innovation in sustainable biopharma.
Leadership Acknowledgment: The company's Founder and CEO, Ryan Saadi, MD, MPH, was recognized for his dedication to advancing health equity and linking societal prosperity with business success.
Focus on T Cell Therapies: Tevogen is developing affordable T cell therapies targeting acute viral infections and cancers, utilizing its proprietary ExacTcell™ platform which has shown positive clinical trial results.
Technological Advancements: The launch of Tevogen.AI, in partnership with Microsoft and Databricks, aims to enhance therapeutic discovery and development through advanced algorithms, supporting the company's mission for accessible healthcare solutions.
TVGN
$0.384+Infinity%1D
Analyst Views on TVGN
About TVGN
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
